Cancer Biomarkers Manufacturers Technological Advancements, Revenue Diversification, Patent Expansions, Cross-border Expansion, Performance Gap Identification, Organizational Growth Plans, Operational Excellence

Cancer Biomarkers Companies and Competitive Landscape

The global cancer biomarkers market was estimated at US$ 30.39 billion in 2023 and is projected to grow to US$ 113.54 billion by 2034, rising at a compound annual growth rate (CAGR) of 12.73% from 2024 to 2034.

Top Companies in the Cancer Biomarkers Market

• Abbott
• Sino Biological Inc
• Hologic, Inc
• Agilent Technologies
• Merck & Co. Inc
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Affymetrix Inc
• Thermo Fisher Scientific Inc
• QIAGEN

Recent Announcements by Industry Leaders

In November 2024, to transform cancer research and care through ethical AI, the Cancer AI Alliance brings together leading cancer centers and AI experts. CAIA is coordinated by the Fred Hutch Cancer Center with assistance from AWS, Deloitte, Microsoft, and NVIDIA, totaling more than $40 million.

Recent Developments in the Cancer Biomarkers Market

• In August 2024, in order to quickly match patients with targeted medicines, the FDA approved the Illumina cancer biomarker test with two companion diagnostics.
• In June 2024, the National Biomarker Centre for Cancer Research UK opened. Experts will be able to identify cancer sooner when there are often more treatment choices, according to this new National Biomarker Center.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com